Permixon® 160 mg

DRUG2 trials

Sponsors

Pierre Fabre Medicament

Conditions

Benign Prostatic Hyperplasia (BPH)

Phase 4

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)

CompletedNCT01604811

Pierre Fabre MedicamentBenign Prostatic Hyperplasia (BPH)

Start: 2012-06-30End: 2013-10-31Updated: 2014-01-15

PERmixon® in LUTS Evaluation Study (PERLES)

CompletedNCT02121613

Pierre Fabre MedicamentBenign Prostatic Hyperplasia (BPH)

Start: 2014-04-30End: 2016-06-30Updated: 2016-09-02